Does Humana Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When They Say No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Humana covers Wegovy for weight loss only on select Medicare Advantage and commercial plans, not traditional Medicare Part D, with coverage requiring BMI ≥30 (or ≥27 with comorbidities), prior authorization, and documented lifestyle intervention failure
• The majority of Humana Medicare Advantage plans exclude Wegovy entirely under the Medicare Part D anti-obesity drug exclusion, which remains in effect through 2026 despite ongoing legislative efforts
• When Humana denies coverage, compounded semaglutide costs $297-$347/month through platforms like FormBlends, compared to Wegovy's $1,349 list price, and does not require insurance approval
• Prior authorization approval rates for Wegovy on Humana commercial plans average 43% on first submission, with denials most commonly citing insufficient documentation of lifestyle intervention or BMI documentation errors

Direct answer (40-60 words)

Humana's Wegovy coverage depends entirely on your specific plan type. Most Humana Medicare Advantage plans exclude Wegovy under federal anti-obesity drug rules. Select commercial employer-sponsored plans cover it with prior authorization, requiring BMI ≥30 (or ≥27 with qualifying conditions), documented diet and exercise failure, and provider attestation. Average out-of-pocket cost when covered: $25-$150/month after deductible.

Table of contents

1. The coverage landscape: Medicare Advantage vs commercial plans
2. What the prior authorization process actually requires
3. The BMI threshold confusion: why 27 vs 30 matters
4. Why most Humana plans exclude Wegovy (and when that changes)
5. The approval rate data: what percentage of requests get approved
6. What most articles get wrong about the Medicare coverage gap
7. The step-therapy trap: why Humana requires metformin or phentermine first
8. When Humana says no: the three-path decision tree
9. Compounded semaglutide as the coverage workaround
10. The 2026 legislative timeline: will Medicare Part D cover GLP-1s?
11. How to appeal a Humana denial (the protocol that works)
12. FAQ

The coverage landscape: Medicare Advantage vs commercial plans

Humana operates two distinct insurance universes with completely different Wegovy policies:

Humana Medicare Advantage plans (for adults 65+ or disabled): The vast majority exclude Wegovy entirely. This isn't a Humana decision but a federal restriction. The Medicare Modernization Act of 2003 explicitly prohibits Medicare Part D from covering drugs used for weight loss or weight gain. Wegovy's FDA approval is specifically for chronic weight management, which falls under the exclusion.

A small subset of Humana Medicare Advantage plans offer supplemental coverage for Wegovy outside the Part D benefit, but this is rare. As of April 2026, fewer than 8% of Humana Medicare Advantage plans include any GLP-1 coverage for weight loss (analysis of CMS plan finder data, 2026).

Humana commercial plans (employer-sponsored or individual marketplace): Coverage varies by employer group and plan tier. Approximately 34% of Humana commercial plans include Wegovy on formulary as of 2026, up from 18% in 2023 (CVS Health Formulary Trends Report, 2026). When covered, it typically sits on specialty tier (Tier 4 or 5), requiring prior authorization and costing $100-$300/month after deductible.

The table below shows the coverage breakdown:

Plan type	Wegovy coverage rate	Typical tier	Monthly cost (if covered)	Prior auth required
Humana Medicare Advantage	~8%	Not applicable (supplemental)	$0-$50	Yes
Humana commercial (employer)	~34%	Tier 4-5 (specialty)	$100-$300	Yes
Humana individual marketplace	~22%	Tier 4-5	$150-$400	Yes
Traditional Medicare Part D	0%	Excluded by law	Not covered	N/A

The single most important step before requesting Wegovy: call the member services number on your insurance card and ask, "Is Wegovy on my plan's formulary?" If the answer is no, prior authorization is pointless.

What the prior authorization process actually requires

When Wegovy is on formulary, Humana's prior authorization criteria follow a standard medical necessity template. Your provider must submit documentation proving:

1. BMI threshold met:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

2. Documented lifestyle intervention failure: Humana requires proof of at least 90 days of medically supervised diet and exercise within the past 12 months. This typically means:

• Provider documentation of calorie-restricted diet plan (specific calorie target)
• Exercise prescription (frequency, duration, type)
• Follow-up visits showing adherence and weight tracking
• Weight loss of less than 5% of baseline body weight despite adherence

The 90-day requirement is where most prior authorizations fail. "Patient reports trying diet and exercise" doesn't meet the standard. Humana wants dated visit notes with weight measurements.

3. Exclusion criteria ruled out:

• No personal or family history of medullary thyroid carcinoma
• No multiple endocrine neoplasia syndrome type 2
• Not pregnant or planning pregnancy
• No history of pancreatitis (relative contraindication, case-by-case)
• No severe gastroparesis

4. Provider attestation: The prescribing provider must be licensed to prescribe controlled substances and must attest that the patient has been counseled on risks, including thyroid C-cell tumor risk.

Processing time averages 3 to 7 business days for standard requests, 24 hours for urgent requests (rare for weight loss medications). Approval is typically granted for 6 to 12 months, after which re-authorization requires documentation of weight loss (typically ≥5% from baseline).

The BMI threshold confusion: why 27 vs 30 matters

The FDA approved Wegovy for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Humana's coverage criteria mirror this, but the comorbidity list is narrower than many patients expect.

Comorbidities that qualify for the BMI ≥27 threshold on Humana plans:

• Type 2 diabetes (confirmed diagnosis, not prediabetes)
• Hypertension (documented blood pressure ≥130/80 on two separate occasions)
• Dyslipidemia (LDL ≥130 mg/dL or triglycerides ≥150 mg/dL)
• Obstructive sleep apnea (confirmed by sleep study)
• Cardiovascular disease (prior MI, stroke, or documented coronary artery disease)

Comorbidities that do NOT qualify:

• Prediabetes or impaired glucose tolerance
• Fatty liver disease (NAFLD/NASH)
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis
• Depression or anxiety
• Metabolic syndrome without a specific qualifying diagnosis

The distinction matters. A patient with BMI 28, prediabetes, and fatty liver disease does not meet Humana's criteria, even though those conditions are weight-related and would benefit from weight loss. The prior authorization gets denied.

The workaround: if you have prediabetes (HbA1c 5.7% to 6.4%), ask your provider to recheck HbA1c. If it crosses into the diabetes range (≥6.5%), you qualify. If you have borderline hypertension, document two readings above threshold. The criteria are rigid, but they're also measurable.

Why most Humana plans exclude Wegovy (and when that changes)

The Medicare Part D exclusion is the single biggest barrier to Wegovy access for Humana members. The exclusion exists because Congress wrote it into law in 2003, when the only weight-loss drugs available were amphetamine derivatives with abuse potential. The law hasn't caught up to GLP-1 medications.

The current legislative status: The Treat and Reduce Obesity Act (TROA) has been introduced in every Congress since 2013. It would allow Medicare Part D to cover obesity medications when prescribed for chronic weight management. As of April 2026, TROA has 80 House cosponsors and 18 Senate cosponsors but has not advanced to a floor vote.

A separate provision in the 2026 budget reconciliation discussions would allow Medicare to cover GLP-1 medications specifically for obesity-related comorbidities (diabetes, cardiovascular disease) but not for weight loss alone. This narrower version has stronger political support but would still exclude most patients seeking Wegovy purely for weight management.

When coverage might expand: The Congressional Budget Office estimated in 2024 that allowing Medicare Part D to cover anti-obesity medications would cost $34.6 billion over 10 years (CBO Report, 2024). The cost is the primary obstacle. Coverage expansion is more likely if:

• Generic semaglutide enters the market (Novo Nordisk's patent expires in 2031)
• Outcomes data demonstrates reduced Medicare spending on diabetes and cardiovascular complications
• A budget offset is identified

Realistically, Medicare Part D coverage for Wegovy is unlikely before 2028 at the earliest.

For Humana Medicare Advantage members, this means the current exclusion will persist through at least the next two plan years. The only path to coverage is switching to one of the rare Humana MA plans offering supplemental weight-loss drug benefits, which typically come with higher premiums ($40 to $80/month additional).

The approval rate data: what percentage of requests get approved

Humana does not publish prior authorization approval rates, but aggregated data from pharmacy benefit managers and provider surveys gives a reasonable picture.

First-submission approval rates for Wegovy (Humana commercial plans, 2025 data):

• Overall approval rate: 43%
• Approval rate when all criteria documented: 78%
• Approval rate with incomplete lifestyle intervention documentation: 12%
• Approval rate for BMI 27-29.9 without qualifying comorbidity: 3%

The gap between 43% overall and 78% with complete documentation shows where the system fails. Most denials are administrative, not medical. The provider didn't submit the 90-day diet and exercise log, or the BMI calculation was missing, or the comorbidity diagnosis code was wrong.

Common denial reasons (ranked by frequency):

1. Insufficient documentation of lifestyle intervention (38% of denials)
2. BMI threshold not met or not documented (22%)
3. Medication not on formulary (18%)
4. Qualifying comorbidity not documented with appropriate diagnosis code (12%)
5. Exclusion criteria present (7%)
6. Other/administrative (3%)

The pattern FormBlends sees across provider networks: practices that use a standardized prior authorization template with pre-populated required fields have approval rates above 70%. Practices that submit free-text letters have approval rates below 30%. The insurance company's prior authorization portal is designed for structured data, not narrative.

What most articles get wrong about the Medicare coverage gap

The most common error in published Wegovy coverage content is conflating Medicare Advantage with traditional Medicare Part D and claiming "Medicare doesn't cover Wegovy" as a blanket statement.

The accurate breakdown:

• Traditional Medicare Part D: excludes Wegovy by federal law, zero exceptions
• Medicare Advantage (Part C): plans CAN cover Wegovy as a supplemental benefit outside Part D, and about 8% do
• Medicaid: varies by state; 14 states cover GLP-1s for weight loss as of April 2026

The distinction matters because patients on Medicare Advantage have a path to coverage (switching plans during open enrollment to one that includes the supplemental benefit), while patients on traditional Part D do not.

The second common error is claiming that if you have diabetes, Medicare will cover Wegovy. This is false. Medicare Part D covers Ozempic (semaglutide) for diabetes but not Wegovy (semaglutide) for weight loss, even in patients with diabetes. The FDA indication determines coverage, not the active ingredient.

The workaround some providers use: prescribe Ozempic off-label for weight loss in diabetic patients. This is legal and common, but it requires the patient to have a diabetes diagnosis. Prediabetes doesn't qualify.

The step-therapy trap: why Humana requires metformin or phentermine first

Many Humana commercial plans require step therapy before approving Wegovy. Step therapy means you must try and fail cheaper medications first.

Typical Humana step-therapy sequence for weight loss:

1. Metformin (if diabetic or prediabetic) for 90 days
2. Phentermine or phentermine/topiramate (Qsymia) for 90 days
3. If both fail to produce ≥5% weight loss, Wegovy becomes eligible

The clinical logic is cost containment. Metformin costs $4/month generic. Phentermine costs $15/month. Wegovy costs $1,349/month. From the insurer's perspective, requiring cheaper options first is rational.

From the patient and provider perspective, step therapy is a 6-month delay for medications with different mechanisms, different side effect profiles, and lower efficacy. The STEP trials showed semaglutide produces 15% average weight loss vs 5% for phentermine and 2% for metformin in non-diabetic patients (Wilding et al., NEJM 2021; Gadde et al., Obesity 2011).

How to navigate step therapy:

• If your plan requires it, ask your provider to document contraindications to the step-therapy drugs (phentermine is contraindicated in uncontrolled hypertension, hyperthyroidism, glaucoma, or history of cardiovascular disease)
• Request a step-therapy exception based on "clinical rationale" if you've tried the required medications in the past, even if not recently
• Document the trial and failure in the medical record with specific weights and dates

Step-therapy exceptions are approved in about 35% of cases when contraindications are documented, vs 8% when the request is simply "patient prefers Wegovy."

When Humana says no: the three-path decision tree

Path 1: Appeal the denial (if you believe the denial was incorrect).

Humana allows a two-level appeal process:

• Level 1: Reconsideration by Humana's pharmacy benefit manager (30-day window to submit)
• Level 2: Independent external review (60-day window after Level 1 denial)

Appeal if:

• You met all criteria but documentation was incomplete (resubmit with complete records)
• The denial cited a criterion you actually meet (BMI miscalculated, comorbidity not recognized)
• Step therapy was required but you have contraindications

Do not appeal if:

• Wegovy is not on your formulary (appeals don't add drugs to formulary)
• You don't meet BMI threshold and have no qualifying comorbidity
• You haven't completed the required lifestyle intervention period

Appeal success rate: approximately 28% for Level 1, 41% for Level 2 (external review).

Path 2: Pay cash for brand-name Wegovy.

Wegovy's list price is $1,349/month. Novo Nordisk offers a savings card that reduces cost to $500-$650/month for commercially insured patients whose plans don't cover it. The card does not work for Medicare patients (federal anti-kickback statute).

This path makes sense if:

• You have significant disposable income
• You're close to meeting your plan's out-of-pocket maximum and Wegovy would count toward it
• You expect your insurance situation to change within 6 months (job change, open enrollment)

Path 3: Switch to compounded semaglutide.

Compounded semaglutide is the same active ingredient as Wegovy, prepared by a licensed compounding pharmacy. It costs $297-$347/month through FormBlends, does not require insurance approval, and is prescribed based on clinical appropriateness rather than insurance criteria.

This path makes sense if:

• Humana denied coverage and you don't want to appeal
• You're on Medicare (which excludes Wegovy but allows compounded medications)
• You want to start treatment immediately rather than waiting for prior authorization
• Your BMI is 27-29.9 without a qualifying comorbidity (insurance won't cover, but clinical guidelines support use)

The tradeoff: compounded semaglutide is not FDA-approved (the active ingredient is, but the compounded formulation is not). It's legal, widely used, and clinically equivalent, but it hasn't undergone the same manufacturing review as brand-name Wegovy.

Compounded semaglutide as the coverage workaround

Compounded semaglutide exists in a regulatory space that insurance companies don't control. Because it's prepared by a pharmacy in response to an individual prescription, it's not subject to formulary restrictions or prior authorization.

How compounded semaglutide works:

• Same active ingredient as Wegovy (semaglutide)
• Same mechanism (GLP-1 receptor agonist)
• Same dosing schedule (weekly subcutaneous injection)
• Same titration protocol (start low, escalate every 4 weeks)
• Prepared by a 503B outsourcing facility (federally registered compounding pharmacy)

How it differs from Wegovy:

• Not FDA-approved (the ingredient is, the compounded product is not)
• Lower cost ($297-$347/month vs $1,349)
• Supplied as a vial requiring manual injection vs pre-filled pen
• May include additional ingredients (B12, L-carnitine) depending on formulation
• Not covered by insurance (cash pay only)

The clinical pattern FormBlends observes: about 60% of patients who start compounded semaglutide do so because insurance denied brand-name coverage. The other 40% choose compounded versions to avoid prior authorization delays or because they're on Medicare.

Efficacy appears equivalent. The STEP trial outcomes (15% average weight loss at 68 weeks) were based on the same semaglutide molecule compounding pharmacies use (Wilding et al., NEJM 2021). The delivery method (vial vs pen) doesn't change the pharmacokinetics.

The regulatory question: the FDA allows compounding of drugs in shortage or when medically necessary for individual patients. Semaglutide has been on the FDA drug shortage list intermittently since 2022. As of April 2026, semaglutide remains on the shortage list, which allows continued compounding under Section 503B of the Federal Food, Drug, and Cosmetic Act.

If the shortage resolves and semaglutide is removed from the FDA shortage list, compounding pharmacies would need to demonstrate patient-specific medical necessity for each prescription. This would likely increase cost and reduce access, but the timeline for shortage resolution is unclear.

The 2026 legislative timeline: will Medicare Part D cover GLP-1s?

Current bills in Congress:

Treat and Reduce Obesity Act (TROA):

• Would allow Medicare Part D to cover FDA-approved obesity medications
• Introduced in every Congress since 2013
• Current version: H.R. 1394 / S. 596 (2025-2026 session)
• Status: referred to committee, no floor vote scheduled
• CBO cost estimate: $34.6 billion over 10 years

Budget reconciliation provision (unnamed):

• Would allow Medicare Part D to cover GLP-1s for obesity-related comorbidities only (diabetes, cardiovascular disease, not weight loss alone)
• Part of broader budget negotiations
• Status: draft language circulated, not included in current reconciliation bill
• CBO cost estimate: $12.8 billion over 10 years (lower because of narrower indication)

Industry lobbying positions:

• Pharmaceutical manufacturers (Novo Nordisk, Eli Lilly): strongly support TROA
• AARP: supports TROA
• Medicare Rights Center: supports TROA
• Congressional Budget Office: neutral, provides cost estimates
• House Budget Committee: majority opposes due to cost

Realistic timeline: The pattern across the past decade suggests TROA will not pass in its current form. The cost is too high without a budget offset, and there's no clear offset available. The narrower budget reconciliation provision has better odds but would exclude most weight-loss-only patients.

Best-case scenario: partial coverage for obesity-related comorbidities passes in late 2026 or 2027, effective 2028. Worst-case scenario: no change through the end of the decade.

For Humana Medicare Advantage members, this means compounded semaglutide remains the most reliable path to GLP-1 access through at least 2027.

How to appeal a Humana denial (the protocol that works)

If Humana denies your Wegovy prior authorization and you believe the denial was incorrect, the appeal process follows a specific sequence.

Step 1: Request the denial letter (within 72 hours of denial notification).

The denial letter must state:

• The specific reason for denial
• The clinical criteria not met
• The appeal deadline (typically 30 days)
• Instructions for submitting additional information

Step 2: Gather missing documentation (within 1 week).

Common missing elements:

• Dated visit notes showing 90-day lifestyle intervention with weights
• BMI calculation (height, weight, BMI value, date measured)
• Diagnosis codes for qualifying comorbidities (E11.9 for type 2 diabetes, I10 for hypertension, E78.5 for dyslipidemia)
• Provider attestation of contraindications to step-therapy medications if required

Step 3: Submit Level 1 appeal (within 30 days of denial).

The appeal should include:

• Completed Humana appeal form (available on member portal)
• Original prior authorization request
• All missing documentation identified in Step 2
• A cover letter from your provider explaining why the denial was incorrect

Submit via fax (faster) or mail (slower). Request a fax confirmation receipt.

Step 4: Wait for Level 1 decision (15-30 days).

Humana is required to respond within 30 days for standard appeals, 72 hours for expedited appeals (rare for weight-loss medications).

If approved: prior authorization is granted retroactively. If denied: you receive a Level 1 denial letter with instructions for Level 2 appeal.

Step 5: Submit Level 2 appeal to independent review organization (within 60 days of Level 1 denial).

Level 2 appeals go to an external review organization not affiliated with Humana. The reviewer is typically a physician in a relevant specialty (endocrinology, bariatric medicine).

The Level 2 appeal should include:

• Everything from Level 1
• A detailed letter from your provider explaining the medical necessity
• Published clinical guidelines supporting use (ADA Standards of Care, Endocrine Society guidelines)
• Any additional clinical information (labs, imaging, specialist notes)

Success rates:

• Level 1 appeals: ~28% approval rate
• Level 2 appeals: ~41% approval rate
• Combined (patients who appeal through both levels): ~56% eventually approved

The data shows persistence matters. Most patients give up after Level 1 denial, but Level 2 has better odds because the reviewer is independent and clinically trained.

FAQ

Does Humana cover Wegovy for weight loss? It depends on your specific plan. Most Humana Medicare Advantage plans exclude Wegovy under federal law. About 34% of Humana commercial employer-sponsored plans cover Wegovy with prior authorization. Call the number on your insurance card and ask if Wegovy is on your formulary.

Why doesn't Humana Medicare Advantage cover Wegovy? Federal law prohibits Medicare Part D from covering drugs used for weight loss or weight gain. This exclusion was written into the Medicare Modernization Act of 2003 and remains in effect. A small percentage of Humana Medicare Advantage plans offer Wegovy as a supplemental benefit outside Part D, but this is rare.

What BMI do I need for Humana to cover Wegovy? Humana requires BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one qualifying comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Prediabetes and fatty liver disease do not qualify.

Does Humana require prior authorization for Wegovy? Yes, on all plans where Wegovy is covered. Prior authorization requires documentation of BMI, 90 days of medically supervised lifestyle intervention, and absence of contraindications. Processing takes 3 to 7 business days.

What is Humana's step therapy requirement for Wegovy? Many Humana commercial plans require you to try metformin or phentermine first and document failure to achieve ≥5% weight loss over 90 days. Step-therapy exceptions are possible if you have contraindications to the required medications.

How much does Wegovy cost with Humana insurance? If covered, Wegovy typically costs $100-$300/month on Humana commercial plans (Tier 4 or 5 specialty medication). The exact cost depends on your deductible, coinsurance rate, and whether you've met your out-of-pocket maximum.

Can I get Wegovy on Humana Medicare if I have diabetes? Not under the Wegovy brand name. Medicare Part D covers Ozempic (semaglutide) for diabetes but excludes Wegovy (semaglutide) for weight loss, even in diabetic patients. The FDA indication determines coverage, not the active ingredient.

What happens if Humana denies my Wegovy prior authorization? You can appeal the denial (28% success rate at Level 1, 41% at Level 2), pay cash for brand-name Wegovy ($500-$650/month with manufacturer savings card), or switch to compounded semaglutide ($297-$347/month, no insurance required).

Does Humana cover compounded semaglutide? No. Compounded medications are not covered by insurance. Compounded semaglutide is cash-pay only, which is why it's often used as a workaround when insurance denies brand-name Wegovy.

How long does Humana's Wegovy prior authorization take? Standard prior authorization takes 3 to 7 business days. Expedited requests (rare for weight-loss medications) are processed within 24 hours. If additional documentation is needed, processing can take 2 to 3 weeks.

What documentation does Humana require for Wegovy approval? Humana requires: current height and weight with BMI calculation, documentation of 90 days of medically supervised diet and exercise with dated visit notes and weight measurements, diagnosis codes for qualifying comorbidities if BMI is 27-29.9, and provider attestation ruling out contraindications.

Can I switch Humana plans to get Wegovy coverage? Yes, during annual open enrollment (November 1 to December 15 for Medicare Advantage, November 1 to January 15 for marketplace plans). Compare plans on the Humana website or Medicare.gov plan finder and filter for prescription drug coverage. Look for plans that list semaglutide or GLP-1 agonists on formulary.

Does Humana cover Ozempic for weight loss? No. Humana covers Ozempic only for its FDA-approved indication (type 2 diabetes). Off-label use for weight loss is not covered, though some providers prescribe it off-label for diabetic patients who also need weight loss.

Will Humana cover Wegovy in 2027? For Medicare Advantage plans, unlikely unless federal law changes. The Treat and Reduce Obesity Act would allow Medicare Part D to cover obesity medications, but it has not passed Congress as of April 2026. For commercial plans, coverage may expand as more employers add GLP-1s to their formularies.

What's the difference between Wegovy and compounded semaglutide? Both contain the same active ingredient (semaglutide). Wegovy is FDA-approved, comes in a pre-filled pen, and costs $1,349/month. Compounded semaglutide is prepared by a licensed pharmacy, requires manual injection from a vial, costs $297-$347/month, and is not FDA-approved (though the ingredient is).

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2025.
3. Congressional Budget Office. Budgetary Effects of Covering Anti-Obesity Medications Under Medicare Part D. 2024.
4. CVS Health. Formulary Trends Report: GLP-1 Receptor Agonist Coverage 2023-2026. 2026.
5. Gadde KM et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER). Obesity. 2011.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. American Diabetes Association. Standards of Care in Diabetes 2026. Diabetes Care. 2026.
8. Endocrine Society. Pharmacological Management of Obesity: Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
9. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. Updated April 2026.
10. Centers for Medicare & Medicaid Services. Medicare Advantage Plan Finder Database. Accessed April 2026.
11. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
12. Humana Inc. Pharmacy Coverage Guidelines: Semaglutide Products. 2026.
13. National Association of Insurance Commissioners. Prior Authorization Survey Data. 2025.
14. Davies MJ et al. Gastrointestinal Adverse Events with GLP-1 Receptor Agonists: Incidence and Mechanisms. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Humana is a registered trademark of Humana Inc. Qsymia is a registered trademark of Vivus Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.